CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $230.39M, lower than 95% of all stocks globally
- PositionPrice-to-book is 0.88×, lower than 95% of its Biotechnology peers (median 2.86×)
- Interpretations8 currently firing — 8
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
230.39MUSDvs all stocks (USD)
Revenue (TTM)
15.01MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.02xvs all stocks
52-Week Change
-27.15%vs all stocks
Market Capitalization
230.39MUSDvs all stocks (USD)
Enterprise Value
-11.49MUSDvs all stocks (USD)
Forward P/E
-1.76xvs Biotechnology peers
Price to Sales (TTM)
15.35xvs Biotechnology peers
Price to Book (MRQ)
0.8783xvs Biotechnology peers
Enterprise to Revenue
-0.7650xvs Biotechnology peers
Enterprise to EBITDA
0.1190xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-655.84%vs Biotechnology peers
Return on Assets (TTM)
-11.78%vs Biotechnology peers
Return on Equity (TTM)
-17.16%vs Biotechnology peers
Revenue (TTM)
15.01MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.5610USDUpdated Sep 27, 2026Quarterly Revenue Growth
-100.00%vs Biotechnology peers
Gross Profit (TTM)
-58.34MUSDvs all stocks (USD)
EBITDA (TTM)
44.21MUSDvs all stocks (USD)
Net Income (TTM)
-83.16MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-100.00%vs Biotechnology peers
Operating Cash Flow (TTM)
-47.99MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-27.17MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
244.06MUSDFY2025 · Dec 31, 2025Operating Income
67.57MUSDvs all stocks (USD)
Pre-tax Income
91.90MUSDFY2025 · Dec 31, 2025Income Tax Expense
4.88MUSDFY2025 · Dec 31, 2025Net Income
87.01MUSDFY2025 · Dec 31, 2025EBIT
67.57MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
44.21MUSDFY2025 · Dec 31, 2025Research & Development
129.64MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
46.85MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
87.01MUSDFY2025 · Dec 31, 2025Operating Cash Flow
113.63MUSDFY2025 · Dec 31, 2025Free Cash Flow
112.08MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
288.86MUSDFY2025 · Dec 31, 2025Income Tax Paid
7.14MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
87.01MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.51MUSDFY2025 · Dec 31, 2025Stock-based Compensation
28.70MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.41MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-3.08MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-3.00MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
78.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.55MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.55MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-375.00MUSDFY2025 · Dec 31, 2025Other Financing Charges
-3.76MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-378.76MUSDFY2025 · Dec 31, 2025Shares Outstanding
19.83MSharesUpdated Sep 27, 2026Float Shares
17.76MSharesUpdated Sep 27, 2026Shares Short
1.34MSharesUpdated Sep 27, 2026Short Ratio
7.74daysvs all stocks
Short % of Shares Outstanding
7.79%vs all stocks
% Held by Insiders
3.96%vs all stocks
% Held by Institutions
95.19%vs all stocks
Total Cash (MRQ)
257.61MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
12.99USDUpdated Sep 27, 2026Total Debt (MRQ)
15.72MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0599xvs Biotechnology peers
Current Ratio (MRQ)
21.96xvs Biotechnology peers
Book Value per Share (MRQ)
13.23USDUpdated Sep 27, 2026Total Assets
338.02MUSDvs all stocks (USD)
Total Current Assets
315.43MUSDFY2025 · Dec 31, 2025Total Liabilities
34.89MUSDFY2025 · Dec 31, 2025Total Non-current Assets
22.59MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
14.47MUSDFY2025 · Dec 31, 2025Total Current Liabilities
20.41MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
287.42MUSDFY2025 · Dec 31, 2025Accounts Receivable
3.57MUSDFY2025 · Dec 31, 2025Accounts Payable
1.97MUSDFY2025 · Dec 31, 2025Short-term Debt
2.41MUSDFY2025 · Dec 31, 2025Other Current Liabilities
217.00KUSDFY2025 · Dec 31, 2025Long-term Debt
14.47MUSDFY2025 · Dec 31, 2025Common Stock (Book)
4.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-481.76MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
303.13MUSDvs all stocks (USD)
Treasury Stock
384.56MUSDFY2025 · Dec 31, 202552-Week Low
9.69USDUpdated Sep 27, 202652-Week High
22.55USDUpdated Sep 27, 202652-Week Change
-27.15%vs all stocks
Beta
1.02xvs all stocks
50-Day MA
10.85USDUpdated Sep 27, 2026200-Day MA
13.18USDUpdated Sep 27, 2026Avg 10-Day Volume
236.09KSharesUpdated Sep 27, 2026Avg 30-Day Volume
192.54KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-3.20USDUpdated Sep 27, 2026Other Income / Expense
24.33MUSDFY2025 · Dec 31, 20258 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cumulative Treasury Stock Significant With Elevated ROE And FCF-To-Equity
It has bought back shares for years, and its equity earns more than its industry and yields heavy free cash flow.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 0.88×, lower than 95% of its Biotechnology peers (median 2.86×)Notable
Price-to-book: 0.88Industry median: 2.86Industry P5: 0.98Peers compared: 260
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 15.35Revenue Growth YoY: -1.00
Prioritizing buybacks over growth reinvestmentNotable
Buyback Intensity: 1.63Revenue Growth YoY: -1.00
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.54
Altman Z-Score 4.4: safe zoneNotable
Altman Z-Score: 4.40
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $230.39M, lower than 95% of all stocks globallySignificant
Market cap (USD): 230,391,924Global P5: 275,556,405.438
Revenue is $15.01M, lower than 95% of all stocks globallySignificant
Revenue (USD): 15,014,000Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Curocell Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shanghai Shenqi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Samyang Biopharmaceuticals Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Fischer Medical Ventures Ltd
Tier 1ProductionApproval-Gated PipelineFlowRule
Sionna Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Immunotech Biopharm Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Terrascend Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Entrada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anavex Life Sciences Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Niagen Bioscience Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Companies that share active interpretations — structural patterns currently present in both stocks.
Sk Biopharmaceuticals Co., Ltd.
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingIndustry-Benchmarked Return on Capital Elevated
Credo Technology Group Holding Ltd.
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingCash Elevated Relative to Current Liabilities and Total Assets
Deckers Outdoor Corporation
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsIndustry-Benchmarked Return on Capital Elevated